Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced systemic mastocytosis Announced a potential best-in-class research program targeting CDK2 for the treatment of multiple cancers with tumor-associated cell cycle defects Plan to provide updates across multiple clinical and research programs at AACR 2021 Annual Meeting Ended 2020 with approximately $1.5 billion in cash
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.
Medication reconciliation is a critical component of the oncology pharmacistʼs duties that has been performed safely over the phone with the patient, caregiver, and pharmacy with the assistance of electronic health records.
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
comments
It was the first time the doctor and I had seen each other in a year. This was in December; I was in for my annual scans and blood work. We made small talk, catching up on the various ways 2020 had ravaged us both. I learned she d been caught in the city s first wave of COVID-19 cases, back in March. She d been seriously ill, and her sense of taste and smell were still not back to normal. Then she asked if I d been sick. No, I told her. I d stayed home, and I wasn t in a high risk group. Well, she said, her eyes flicking down on the results of my latest labs, and your blood type.